NCT03693612
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03693612
Title GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
skin melanoma
transitional cell carcinoma
head and neck squamous cell carcinoma
prostate adenocarcinoma
clear cell renal cell carcinoma
lung non-small cell carcinoma
Therapies
GSK3359609 + Tremelimumab
Paclitaxel
Docetaxel
Cetuximab
Age Groups: senior | adult
Covered Countries USA | CAN | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site New York New York 10016-4744 United States Details
GSK Investigational Site New York New York 10032 United States Details
GSK Investigational Site Pittsburgh Pennsylvania 15232 United States Details
GSK Investigational Site San Antonio Texas 78229 United States Details
GSK Investigational Site Melbourne Victoria 3000 Australia Details
GSK Investigational Site Ottawa Ontario K1H 8L6 Canada Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field